The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

An investigational, novel combination therapy, consisting of an N-methyl-D-aspartate receptor-modulating drug (ketamine) delivered intravenously (IV) in combination with manualized relapse prevention ...

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of ... Johnson's Spravato (esketamine), which was approved ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

Interestingly, the mechanisms of action of many novel antidepressant drugs ... robust and sustained antidepressant effects of (R,S)-ketamine and esketamine. In addition, the breadth of therapeutic ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

However, research into the biological mechanisms of PPD is a challenging task, as normal pregnancy and the postpartum period cause adaptive endocrine changes, which would otherwise be considered ...